Future prospective cohort studies are warranted to confirm whether MetS and MetS components are associated with increased risks of diabetes complications, and randomized controlled trials may also be needed if the findings were confirmed by prospective cohorts, to test the efficacy and effectiveness of insulin sensitizers in the management of LADA for potential cardiovascular benefits. The gene discussed is INS; the disease is metabolic syndrome.